BG Medicine (BGMD) Reports Q3 Loss of $0.27/Share

BG Medicine (: BGMD) reported Q3 EPS of ($0.27), versus ($0.28) reported last year. Revenue for the quarter came in at $334 million, versus $695 million reported last year.

Our operating results in the third quarter of 2015 reflect our ongoing efforts to extend our cash runway through the prudent and disciplined management of our resources," said Paul R. Sohmer, M.D., President and CEO of BG Medicine (the “Company”). “The commercialization of automated testing for galectin-3 in the U.S. was initiated in the third quarter. As a result, we continue to expect that product fees generated through the initial sales of automated tests for galectin-3 in the U.S. and payable to the Company by Abbott will be reported next quarter.”

For earnings history and earnings-related data on BG Medicine (BGMD) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Innovaro (INV) Misses Q2 EPS by 9c